Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00998426 · ClinicalTrials.gov registry record · Phase 4
Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients
A Phase 4 study, sponsored by Georgetown University.
- Completed
- Registry status
- Phase 4
- Development phase
- 5
- Enrollment target
NCT00998426 is a Phase 4 study that has completed, run by Georgetown University. The registered enrollment target is 5 participants.
The verdict
NCT00998426, a Phase 4 study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 5 participants
- Enrollment target
Study Summary
HepaGam B Hepatitis B Immune Globulin (HBIG) solution contains 10% maltose, which could possibly interfere with the measurement of glucose levels when using glucose non-specific tests. The purpose of this study is to determine whether use of HepaGam B HBIG shows an increase in glucose levels in the body using non-specific glucose monitoring, as well as specific glucose monitoring. The sponsor believes that this medication will not cause a significant increase in glucose levels in the body when measured by glucose non-specific tests.
Interventions
- PROCEDURE glucose monitoring before and after HepaGam B administration
- BIOLOGICAL HepaGam B (Hepatitis B Immune Globulin (HBIG))
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00998426
The ClinicalTrials.gov registry entry for NCT00998426 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which glucose monitoring before and after HepaGam B administration is the first listed.
NCT00998426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00998426 about?
NCT00998426 is a clinical study titled "Evaluating Blood Glucose Levels During Infusion With HepaGam B (HBIG) in Post-liver Transplant Patients". HepaGam B Hepatitis B Immune Globulin (HBIG) solution contains 10% maltose, which could possibly interfere with the measurement of glucose levels when using glucose non-specific tests. The purpose of this study is to determine whether use of HepaGam B HBIG shows an increase in glucose levels in the ...
What is the current status of trial NCT00998426?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 5 participants. The study started on 2009-10. Estimated completion is 2011-12.
What interventions are being tested in trial NCT00998426?
The interventions under investigation include: glucose monitoring before and after HepaGam B administration (PROCEDURE), HepaGam B (Hepatitis B Immune Globulin (HBIG)) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00998426?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.